By Pat Anson, Editor
Titan Pharmaceuticals, Inc. (OTCC: TTNP) has announced that it received a letter from the Food and Drug Administration delaying approval for an implantable version of buprenorphine, an opioid addiction treatment drug more widely known as Suboxone.
Titan said the FDA cannot approve the application in its present form for the Probuphine implant and asked for additional information on its effectiveness.
“Titan and our partner, Braeburn Pharmaceuticals, are extremely surprised and disappointed with the FDA’s response,” said Marc Rubin, MD, executive chairman of Titan Pharmaceuticals.
“Given the nationally-recognized, growing and devastating opioid dependence epidemic, there is critical need for new safe and effective treatments that reduce the likelihood of abuse, diversion and accidental pediatric exposure, and Titan and Braeburn remain committed to making Probuphine available for patients that need it.”
Read more at National Pain Report.
(1) Reader Comment
November 12, 2012
October 08, 2012
September 12, 2012
July 23, 2012
June 11, 2019
April 05, 2019
April 01, 2019
March 18, 2019
Oh boy...Your right we hate to hear this. You know why people in pain
Doesn't the 1.5 billion is spent a year give credence to its possitive
Many MS drugs cause PML and deaths too these drugs all need t
I knew him when he was breaking in at a couple of Los Angeles TV stati
Saying there is a 'twist' is the worst type of spoile